Alliance Pharma PLC Total Voting Rights (4337V)

TIDMAPH

RNS Number : 4337V

Alliance Pharma PLC

01 December 2023

 
 For immediate release   01 Dec 2023 
 

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

Total Voting Rights

Alliance Pharma plc (AIM: APH), the international healthcare group, makes the following notification in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1.

As at 30 November 2023 the Company's issued share capital consists of 540,390,080 Ordinary Shares of 1p each.

The total number of voting rights in the Company is 540,390,080 and this figure may be used by shareholders as the denominator for the calculations by which they should determine if they are required to notify their interest in, or change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

For further information:

 
 Alliance Pharma plc                            + 44 (0)1249 466966 
 Head of Investor Relations: Cora McCallum      + 44 (0)1249 705168 
 [e-mail] 
 
                                                    + 44 (0)20 7466 
 Buchanan                                                      5000 
 Mark Court / Sophie Wills 
 [e-mail] 
 
 Deutsche Numis (Nominated Adviser and Joint        + 44 (0)20 7260 
  Broker )                                                     1000 
 Freddie Barnfield / Duncan Monteith / Sher 
  Shah 
 
                                                    + 44 (0)20 7597 
 Investec Bank plc (Joint Broker)                              5970 
 Patrick Robb / Maria Gomez de Olea 
 

About Alliance

Alliance Pharma plc (AIM: APH) is a growing consumer healthcare company . Our purpose is to empower people to make a positive difference to their health and wellbeing by making our trusted and proven brands available around the world.

We deliver organic growth through investing in our priority brands and channels, in related innovation, and through selective geographic expansion to increase the reach of our brands. Periodically, we may look to enhance our organic growth through selective, complementary acquisitions .

Headquartered in the UK, the Group employs around 285 people based in locations across Europe, North America, and the Asia Pacific region. By outsourcing our manufacturing and logistics we remain asset-light and focused on maximising the value we can bring, both to our stakeholders and to our brands. For more information on Alliance, please visit our website : www.alliancepharmaceuticals.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

TVRUPGPPPUPWGPG

(END) Dow Jones Newswires

December 01, 2023 07:23 ET (12:23 GMT)